Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Voriconazole (Pfizer ltd).

P E Verweij1, B E de Pauw, J F Meis

  • 1Departments of Medical Microbiology and Hematology, University Hospital Nijmegen, The Netherlands. p.verweij@mmb.azn.nl

Idrugs : the Investigational Drugs Journal
|August 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential susceptibility of Candida (Candidozyma) auris clades to surface disinfectants.

The Journal of hospital infection·2025
Same author

Genotyping of Candida tropicalis isolates uncovers nosocomial transmission of two lineages in Italian tertiary care hospital.

The Journal of hospital infection·2024
Same author

Comparative in vitro activities of seven antifungal drugs against clinical isolates of Candida parapsilosis complex.

Journal de mycologie medicale·2020
Same author

Clinical relevance of Scedosporium spp. and Exophiala dermatitidis in patients with cystic fibrosis: A nationwide study.

Medical mycology·2020
Same author

Candida blankii: an emerging yeast in an outbreak of fungaemia in neonates in Delhi, India.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same author

Successful Allogenic Stem Cell Transplantation in Patients with Inherited CARD9 Deficiency.

Journal of clinical immunology·2019
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Voriconazole shows promise as a treatment for invasive fungal infections, including aspergillosis and candidiasis, particularly in immunocompromised patients. Clinical trials indicate significant efficacy, even when other antifungals have failed.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Emerging fungal infections pose a significant threat to immunocompromised individuals.
  • Voriconazole is a novel antifungal agent developed by Pfizer.
  • Existing treatments like amphotericin have limitations in efficacy and tolerability.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of voriconazole in treating various fungal infections.
  • To compare voriconazole's activity against other antifungal agents.
  • To assess voriconazole's potential in treating infections caused by resistant fungal strains.

Main Methods:

  • Phase III clinical trials involving immunocompromised patients with aspergillosis and candidiasis.
  • In vitro studies comparing voriconazole's activity against comparator agents.

Related Experiment Videos

  • Analysis of clinical efficacy data from patient trials.

    • Main Results:

    • Voriconazole demonstrated clinical efficacy of at least 69% in trials.
    • The compound was effective in patients who did not respond to amphotericin B.
    • In vitro studies showed voriconazole to be highly active against certain Scedosporium species.

    Conclusions:

    • Voriconazole is effective and well-tolerated for treating invasive aspergillosis and candidiasis in various patient populations.
    • The drug exhibits an extended spectrum of activity compared to existing treatments.
    • Voriconazole holds potential for treating serious fungal infections affecting the eye and brain.